Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA
Authors:
- Susan Cu-UvinSCSusan Cu-Uvin
- Angela M. CaliendoACAngela M. Caliendo
- Steven ReinertSRSteven Reinert
- Albert ChangACAlbert Chang
- Catherine Juliano-RemollinoCJCatherine Juliano-Remollino
- Timothy P. FlaniganTFTimothy P. Flanigan
- Kenneth H. MayerKMKenneth H. Mayer
- Charles C. J. CarpenterCCCharles C. J. Carpenter
- 1 March 2000
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 14 (4) , 415-421
Abstract
To determine the frequency of cervicovaginal lavage and plasma HIV-1 RNA levels that are below detectable levels (< 400 copies/ml) among women on highly active antiretroviral therapy (HAART), non-HAART and on no therapy. To compare the effect of initiating HAART on the timing of HIV-1 RNA suppression in the blood plasma and genital tract among antiretroviral-naïve women. Data were obtained from 205 HIV-infected women with paired plasma and cervicovaginal lavage viral load measurements. Seven antiretroviral-naïve women starting HAART had viral load measurements performed daily for one week, at 2 weeks and at 1 month after initiating therapy. Viral load quantification was carried out by nucleic acid sequence-based amplification assay. The lower limit of detection was 400 copies/ml. Plasma and cervicovaginal HIV-1 RNA was detectable in 71 and 26% of the women, respectively. Among women with plasma viral loads less than 400, 400–9999, and 10 000 copies/ml or over, genital tract HIV-1 RNA was detected in 3, 17 and 48%, respectively (P < 0.001). Fifty-one per cent of the women with CD4 cell counts of less than 200/mm3 had detectable cervicovaginal viral loads compared with 18% among women with CD4 cell counts of 200/mm3 or over (P < 0.001). Cervicovaginal HIV-1 RNA was less than 400 copies/ml in 85% of those on HAART, 69% of those on non-HAART and 69% of those on no therapy (P < 0.045). In seven antiretroviral-naïve women initiating HAART, cervicovaginal HIV-1 RNA decreased by 0.7–2.1 log10 within 1–14 days of starting therapy. The cervicovaginal HIV-1 RNA level was positively correlated with plasma HIV-1 RNA and negatively with the CD4 cell count. The use of HAART was significantly associated with below-detectable levels of HIV-1 RNA in both plasma and the genital tract. HIV-1 RNA suppression in the genital tract may occur rapidly after initiating therapy.Keywords
This publication has 24 references indexed in Scilit:
- Distinct Determinants of Human Immunodeficiency Virus Type 1 RNA and DNA Loads in Vaginal and Cervical SecretionsThe Journal of Infectious Diseases, 1998
- Human Immunodeficiency Virus Type 1 RNA Shedding in the Female Genital TractThe Journal of Infectious Diseases, 1998
- HIV-1 detection in cervicovaginal secretions during pregnancyAIDS, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Effect of antiviral treatment on the shedding of HIV-1 in semenAIDS, 1997
- Antiretroviral Therapy for HIV Infection in 1997JAMA, 1997
- Effects of Reverse Transcriptase Inhibitor Therapy on the HIV-1 Viral Burden in SemenJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- Genital Shedding of Human Immunodeficiency Virus Type 1 DNA during Pregnancy: Association with Immunosuppression, Abnormal Cervical or Vaginal Discharge, and Severe Vitamin A DeficiencyThe Journal of Infectious Diseases, 1997
- Association Between Cervical Inflammation And Cervical Shedding Of Human Immunodeficiency Virus DNAThe Journal of Infectious Diseases, 1994
- Isolation of Human Immunodeficiency Virus from Genital Ulcers in Nairobi ProstitutesThe Journal of Infectious Diseases, 1989